Sign in
Taking people in South AfricaNo phase

Screening South African women for cervical pre-cancer using HPV testing

Studies HPV tests and cytology to screen women for cervical pre-cancer and cancer.

Key facts

Who runs it
University of Pretoria
Where
Pretoria, South AfricaSee the site
Trial code
Registry title
Screening Study for Cervical Pre-cancer and Cancer Prevention in South African Women.
Status
Recruiting
People taking part
1,500 people, planned
Started
Dec 2016
Expected to end
Dec 2038
Type of study
Observational, 3 groups
Treatments tested
  • Screening
  • Colposcopy
  • LLETZ
Record updated
7 July 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for women aged 25 to 75 in South Africa who come for or ask for a cervical cancer screening test. Women with and without HIV can join.

Age
25 to 75 years
Sex
Women only
Earlier treatment
Women with current or previous treatment for gynaecological cancer cannot join.

Main reasons for not taking part

  • Current pregnancy
  • Hysterectomy
  • Current or previous treatment for gynaecological cancer
  • Hesitant or unable to undergo screening and treatment if indicated

The registry criteria, word for word

Show all 7 criteriaShow less

Who can take part

  • Informed consent accepted and signed
  • Health seeking behaviour or request for a cervical cancer screening test
  • Willing and able to receive test result by automated text message or clinic visit

Who cannot take part

  • Current or previous treatment for gynaecological cancer
  • Current pregnancy
  • Hysterectomy
  • Hesitant or unable to undergo screening and treatment if indicated

The main criteria, as questions

These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Are you between 25 and 75 years old?

This trial is currently available in South Africa.

  • Steve Biko Academic HospitalPretoria, South AfricaContact: Cathy Visser, MScTaking people

About the trial

What the trial wants to find out

Nearly 8 000 new cervical cancer cases are diagnosed in South Africa per year; many are still undiagnosed and about 50% of diagnosed cases succumb per year. Although the current prevalence of pre-cancer cervical disease is largely unknown, data from local studies suggest regional differences and an increase in the prevalence of cytological abnormalities when compared with historical data. Low frequency in cytology screening is the primary factor attributable to development of invasive cervical cancer and almost one-third of all cervical cancer patients had previous negative cytology. Due to the low sensitivity of cytology it can be assumed that the true prevalence of pre-cancer disease is underestimated by all available data. One round of optimal cervical cytology will detect around 50% of existing pre-cancer cervical disease as identified and proven using colposcopy and directed biopsy. It is now widely accepted that primary screening with a human papilloma virus (HPV) test can improve the sensitivity of screening and that even a single round of HPV screening can rapidly reduce the incidence of invasive cervical cancer and related mortality within a few years.

Read full original descriptionShow less

South Africa has a high prevalence of HIV infection and a delay in or failure to initiate antiretroviral therapy (ART). These facts, together with the largely unscreened status of the female population and the high incidence of cervical cancer all suggest that HPV infection and precursors to cervical cancer are both unusually common among South African women. Accurate current knowledge of the performance of newer generation HPV based screening tests in HIV-infected and general female population are essential for cost-analysis and planning for national prevention and screening programs. This study will aim to demonstrate the feasibility and efficacy of new generation HPV deoxyribonucleic acid (DNA) based screening assays in a South African setting.

The investigators hypothesize that HPV testing followed by normal and special cytology tests will be a successful screening model for a South African population.

The 3 groups in the trial

  • HIV pos

    those who serologically tested positive for HIV

    Treatment: Screening, Colposcopy, and LLETZ

  • HIV neg

    those who serologically tested negative for HIV

    Treatment: Screening, Colposcopy, and LLETZ

  • HIV unk

    those with no available serological test for HIV

    Treatment: Screening, Colposcopy, and LLETZ

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Primary HPV Screening as an Indicator of Cervical Pre-invasive and Invasive Neoplasia in HIV-positive and -Negative Southern African Women
Plain-language title
Screening South African women for cervical pre-cancer using HPV testingGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Criteria questions
Built from NCT02956031, who can take part
Publications
Record updated
7 July 2026